Table 1 Characteristics and quality assessment results of included studies.
ID | Time of ACs use | country | cancer type | ICI treatment | ICIs line | ACs type | Sample size (Y/N) | Outcome | Median PFS (Users vs. non-users) (Month) | Median OS (Users vs. non-users) (Month) | Analysis model | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cortellini 2020 | baseline | Italy | NSCLC | Pembrolizumab | First | New oral anticoagulants | 145/1012 | PFS/OS | 6.3 vs. 10.9 | 12.4 vs. 18.9 | MVA/ UVA | 7 |
Melanoma | Nivolumab | Non-first | Low molecular weight heparin | |||||||||
RCC | Atezolizumab | Vitamin K antagonists | ||||||||||
Others | Others | |||||||||||
Johannet 2021 Nichetti | (0, NR) (0, NR) | America Italy | Melanoma | anti-CTLA-4 | First | Direct thrombin inhibitor | 120/948 | PFS/OS PFS/OS | NA 2.3 vs. 4.2 | NA 7.8 vs. 10.3 | MVA/ UVA MVA/ | 7 6 |
Lung cancer | anti-PD-1 or anti-PD-L1 | Non-first | Factor Xa inhibitor | |||||||||
Others | anti-PD-1 + anti-CTLA-4 | Heparin product | ||||||||||
Vitamin K antagonist | ||||||||||||
NSCLC | anti-CTLA-4 | NA | NA | 47/217 | ||||||||
2019 Haist 2021 | baseline | German | Melanoma | anti-PD-1 or anti-PD-L1 | First Non-first | Factor Xa inhibitor Vitamin K antagonist | 76/280 | PFS/OS | 4.0 vs. 4.0 | 39 vs. 51.0 | UVA MVA/ UVA | 7 |
anti-PD-1 + anti-CTLA-4 | ||||||||||||
anti-PD-1 | ||||||||||||
Sainz 2020 | baseline | Spain | NSCLC Melanoma RCC | anti-CTLA-4 | Heparin product | OS | MVA | 6 | ||||
anti-CTLA-4 | First | NA | 17/229 | NA | NA | |||||||
anti-PD-1 or anti-PD-L1 | ||||||||||||
anti-PD-1 + anti-CTLA-4 | ||||||||||||
Others |
